Skip to main content
AmigoFish

Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3

From BiotechTV - News · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.

Back to BiotechTV - News · Report a problem